$0.36
+0.02 (+6.22%)
Open$0.35
Previous Close$0.34
Day High$0.36
Day Low$0.34
52W High$1.39
52W Low$0.22
Volume—
Avg Volume235.3K
Market Cap5.05M
P/E Ratio—
EPS$-0.93
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+5,363.0% upside
Current
$0.36
$0.36
Target
$19.88
$19.88
$13.54
$19.88 avg
$24.91
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 291.0K | 288.1K | 653.1K |
| Net Income | -17,720,136 | -15,791,783 | 116.0K |
| Profit Margin | -6,092.8% | -5,788.1% | 17.8% |
| EBITDA | -18,982,042 | -17,856,163 | 172.6K |
| Free Cash Flow | — | — | 101.3K |
| Rev Growth | +1.0% | +1.0% | -9.1% |
| Debt/Equity | — | — | 0.30 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |